Tag Archives: IOVA

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics Inc (NASDAQ: IOVA), Synergy Pharmaceuticals Inc (NASDAQ: SGYP) and Histogenics (NASDAQ: HSGX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Iovance Biotherapeutics Inc (NASDAQ: IOVA), Synergy Pharmaceuticals Inc (NASDAQ: SGYP) and Histogenics (NASDAQ: HSGX) with bullish sentiments. Iovance Biotherapeutics Inc (NASDAQ: IOVA)

Oppenheimer Keeps a Buy Rating on Iovance Biotherapeutics Inc

In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on Iovance Biotherapeutics Inc (NASDAQ: IOVA), with a price target of $22. The company’s shares closed yesterday at $14.85. Breidenbach noted: “Thursday, on its 1Q18 earnings call,

Oppenheimer Believes Iovance Biotherapeutics Inc (NASDAQ: IOVA) Won’t Stop Here

Oppenheimer analyst Mark Breidenbach reiterated a Buy rating on Iovance Biotherapeutics Inc (NASDAQ: IOVA) today and set a price target of $22. The company’s shares closed yesterday at $19.15, close to its 52-week high of $19.60. Breidenbach said: “On Monday,

Iovance Biotherapeutics Inc Receives a Rating Update from a Top Analyst

B.Riley FBR analyst Madhu Kumar reiterated a Hold rating on Iovance Biotherapeutics Inc (NASDAQ: IOVA) today and set a price target of $22. The company’s shares closed yesterday at $19.15, close to its 52-week high of $19.60. Kumar observed: “Yesterday,

H.C. Wainwright Keeps a Buy Rating on Iovance Biotherapeutics Inc

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Iovance Biotherapeutics Inc (NASDAQ: IOVA), with a price target of $16. The company’s shares closed yesterday at $8.70, close to its 52-week high of $9.50.

Iovance Biotherapeutics Inc Gets a Buy Rating from B.Riley FBR

B.Riley FBR analyst Madhu Kumar reiterated a Buy rating on Iovance Biotherapeutics Inc (NASDAQ: IOVA) today and set a price target of $18. The company’s shares closed on Friday at $8.05, close to its 52-week high of $8.60. Kumar observed: